Héliton S Antunes1, Daniel Herchenhorn2, Isabele A Small3, Carlos M M Araújo4, Celia Maria Pais Viégas4, Gabriela de Assis Ramos3, Fernando L Dias5, Carlos G Ferreira6. 1. Clinical Research Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil. Electronic address: hspindola@inca.gov.br. 2. Head and Neck Oncology Group, Grupo de Oncologia D'Or, Brazil. 3. Clinical Research Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil. 4. Radiation Oncology Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil. 5. Head and Neck Surgery Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil. 6. D'Or Institute for Research and Education, Brazil.
Abstract
BACKGROUND: The impact of low-level laser therapy (LLLT) to prevent oral mucositis in patients treated with exclusive chemoradiation therapy remains unknown. This study evaluated the overall, disease-free and progression-free survival of these patients. METHODS:Overall, disease-free and progression-free survival of 94 patients diagnosed with oropharynx, nasopharynx, and hypopharynx cancer, who participated on a phase III study, was evaluated from 2007 to 2015. The patients were subjected to conventional radiotherapy plus cisplatin every 3weeks. LLLT was applied with an InGaAlP diode (660nm-100mW-1J-4J/cm2). RESULTS: With a median follow-up of 41.3months (range 0.7-101.9), patients receiving LLLT had a statistically significant better complete response to treatment than those in the placebo group (LG=89.1%; PG=67.4%; p=0.013). Patients subjected to LLLT also displayed increase in progression-free survival than those in the placebo group (61.7% vs. 40.4%; p=0.030; HR:1:93; CI 95%: 1.07-3.5) and had a tendency for better overall survival (57.4% vs. 40.4%; p=0.90; HR:1.64; CI 95%: 0.92-2.91). CONCLUSION: This is the first study to suggest that LLLT may improve survival of head and neck cancer patients treated withchemoradiotherapy. Further studies, with a larger sample, are necessary to confirm our findings.
RCT Entities:
BACKGROUND: The impact of low-level laser therapy (LLLT) to prevent oral mucositis in patients treated with exclusive chemoradiation therapy remains unknown. This study evaluated the overall, disease-free and progression-free survival of these patients. METHODS: Overall, disease-free and progression-free survival of 94 patients diagnosed with oropharynx, nasopharynx, and hypopharynx cancer, who participated on a phase III study, was evaluated from 2007 to 2015. The patients were subjected to conventional radiotherapy plus cisplatin every 3weeks. LLLT was applied with an InGaAlP diode (660nm-100mW-1J-4J/cm2). RESULTS: With a median follow-up of 41.3months (range 0.7-101.9), patients receiving LLLT had a statistically significant better complete response to treatment than those in the placebo group (LG=89.1%; PG=67.4%; p=0.013). Patients subjected to LLLT also displayed increase in progression-free survival than those in the placebo group (61.7% vs. 40.4%; p=0.030; HR:1:93; CI 95%: 1.07-3.5) and had a tendency for better overall survival (57.4% vs. 40.4%; p=0.90; HR:1.64; CI 95%: 0.92-2.91). CONCLUSION: This is the first study to suggest that LLLT may improve survival of head and neck cancerpatients treated with chemoradiotherapy. Further studies, with a larger sample, are necessary to confirm our findings.
Authors: Letícia Mello Bezinelli; Luciana Corrêa; Cristina Vogel; Jose Mauro Kutner; Andreza Feitosa Ribeiro; Nelson Hamerschlak; Carlos de Paula Eduardo; Cesar Augusto Migliorati; Fernanda de Paula Eduardo Journal: Support Care Cancer Date: 2021-05-22 Impact factor: 3.603
Authors: Sharon Elad; Praveen Arany; Rene-Jean Bensadoun; Joel B Epstein; Andrei Barasch; Judith Raber-Durlacher Journal: Support Care Cancer Date: 2018-05-22 Impact factor: 3.603
Authors: Thaís Bianca Brandão; Karina Morais-Faria; Ana Carolina Prado Ribeiro; César Rivera; João Victor Salvajoli; Marcio Ajudarte Lopes; Joel B Epstein; Praveen R Arany; Gilberto de Castro; Cesar Augusto Migliorati; Alan Roger Santos-Silva Journal: Support Care Cancer Date: 2018-02-08 Impact factor: 3.603
Authors: Yehuda Zadik; Praveen R Arany; Eduardo Rodrigues Fregnani; Paolo Bossi; Héliton Spindola Antunes; René-Jean Bensadoun; Luiz Alcino Gueiros; Alessandra Majorana; Raj G Nair; Vinisha Ranna; Wim J E Tissing; Anusha Vaddi; Rachel Lubart; Cesar Augusto Migliorati; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Ori Finfter; Batia Avni; Sigal Grisariu; Yaron Haviv; Chen Nadler; Ori Rimon; Yehuda Zadik Journal: Support Care Cancer Date: 2021-01-20 Impact factor: 3.603